Regarding:
KEY POINTS:
- CDPHE is investigating a cluster of Toxic Anterior Segment Syndrome (TASS) among patients following cataract surgeries. All three patients identified received the same type and lot number of ophthalmic viscosurgical device (OVD). The investigation is ongoing.
- CDPHE recommends that health care providers and ophthalmologic suppliers check their supplies of OVDs for Amvisc Plus lot number D130087A, manufactured by Bausch & Lomb. This specific lot number should not be used on patients until more information is available.
- CDPHE requests that any cases of TASS diagnosed between January 1, 2015 - present where Amvisc Plus, (manufactured by Bausch & Lomb) was used, or cases of TASS where the type of OVD is unknown, be reported to the Communicable Disease Branch by contacting Devra Barter at 303-692-2706 or devra.barter@state.co.us.
For further information:
For questions or additional information, please contact Devra Barter (303-692-2706 or devra.barter@state.co.us) in the Communicable Disease Branch at CDPHE.
This blog publishes information typically sent to users of the Colorado Health Facilities Interactive (COHFI) system for health care entities regulated by the Colorado Department of Public Health and Environment. Please note that COHFI is the official medium for business communication between the Department and licensed and/or Medicare/Medicaid certified health care entities. Health care entities should continue to monitor their email accounts routinely.
